SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Liu, Yongzhong ^a   Gao, Lingqiu ^b   Gelman, Irwin H ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKAP12 PROTEIN; ALPHA FETOPROTEIN; BUTYRATE INDUCED TRANSCRIPT 1; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 20A; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2D; GRAVIN PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN P19; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; RAS PROTEIN; REGULATOR PROTEIN; RETINOBLASTOMA BINDING PROTEIN 7; SCAFFOLD PROTEIN; SRC SUPPRESSED C KINASE SUBSTRATE; UNCLASSIFIED DRUG;

ALLELE; ANGIOGENESIS; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; EPITHELIUM CELL; FIBROBLAST CULTURE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TEMPERATURE SENSITIVITY; TUMOR VASCULARIZATION;

A KINASE ANCHOR PROTEINS; ANGIOGENIC PROTEINS; ANIMALS; CELL CYCLE PROTEINS; CELL DIVISION; DNA, COMPLEMENTARY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, SRC; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; NIH 3T3 CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEIN PP60(V-SRC); RATS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33646681027     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-105     Document Type: Article

References (74)

1. Lin X, Nelson PJ, Frankfort B, Tombler E, Johnson R, Gelman IH: Isolation and characterization of a novel mitogenic regulatory gene, 322, which is transcriptionally suppressed in cells transformed by src and ras. Mol Cell Biol 1995, 15:2754-2762.
2. Nauert J, Klauck T, Langeberg LK, Scott JD: Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffolding protein. Current Biology 1997, 7:52-62.
3. Gordon T, Grove B, Loftus JC, O'Toole T, McMillan R, Lindstrom J, Ginsberg MH: Molecular cloning and prelimnary characteriztion of a novel cytoplasmic antigen recognized by myasthenia gravis sera. J Clin Invest 1992, 90:992-999.
4. Xia W, Unger P, Miller L, Nelson J, Gelman IH: The src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 2001, 15:5644-5651.
5. Gelman IH: The role of the SSeCKS/Gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Front Biosci 2002, 7:1797.
6. Lin X, Gelman IH: Re-expression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis. Cancer Res 1997, 57:2304-2312.
7. Lin X, Nelson P, Gelman IH: Regulation of G->S Progression by the SSeCKS Tumor Suppressor: Control of Cyclin D Expression and Cellular Compartmentalization. Mol Cell Biol 2000, 20:7259-7272.
8. Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, Kim YJ, Kim KW: SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med 2003, 9:900-906.
9. Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH: SSeCKS metastasis-suppressing activity correlates with angiogenesis inhibition. Cancer Res 2006 in press.
10. Tusher VG, Tibshirani R, Chu G: Significance analysis of micro-arrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121.
11. Moissoglu K, Gelman IH: v-Src Rescues Actin-Based Cytoskeletal Architecture and Cell Motility, and Induces Enhanced Anchorage-Independence During Oncogenic Transformation of FAK-Null Fibroblasts. J Biol Chem 2003, 278:47946-47959.
12. Lin X, Tombler E, Nelson PJ, Ross M, Gelman IH: A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. J Biol Chem 1996, 271:430-28.
13. Gelman IH, Lee K, Tombler E, Gordon R, Lin X: Control of cytoskeletal architecture by the src-suppressed C kinase substrate, SSeCKS. Cell Motil Cytoskeleton 1998, 41:1-17.
14. Li MS, Li PF, Yang FY, He SP, Du GG, Li G: The intracellular mechanism of alpha-fetoprotein promoting the proliferation of NIH 3T3 cells. Cell Res 2002, 12:151-156.
15. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M, Croce CM, Fusco A: Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002, 21:3190-3198.
16. Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC: CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci USA 2002, 99:207-212.
17. Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH: SSeCKSmetastasis-suppressing activity in MatLyLu prostate cancer cellscor-relates with VEGF inhibition. Cancer Res 2006 in press.
18. Bharti AC, Takada Y, Shishodia S, Aggarwal BB: Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism. J Biol Chem 2004, 279:6065-6076.
19. Sum EY, Shackleton M, Hahm K, Thomas RM, O'Reilly LA, Wagner KU, Lindeman GJ, Visvader JE: Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development. Oncogene 2005,24:4820-4828.
20. Yamada M, Ishii N, Asao H, Murata K, Kanazawa C, Sasaki H, Sugamura K: Signal-transducing adaptor molecules STAM1 and STAM2 are required for T-cell development and survival. Mol Cell Biol 2002, 22:8648-8658.
21. Johnson MD, Wu X, Aithmitti N, Morrison RS: Peg3/Pw1 is a mediator between p53 and Bax in DNA damage-induced neuronal death. J Biol Chem 2002, 277:23000-23007.
22. Shashidhar S, Lorente G, Nagavarapu U, Nelson A, Kuo J, Cummins J, Nikolich K, Urfer R, Foehr ED: GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene 2005, 24:1673-1682.
23. Yamada A, Kawano K, Koga M, Takamori S, Nakagawa M, Itoh K: Gene and peptide analyses of newly defined lung cancer anti-gens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes. Cancer Res 2003, 63:2829-2835.
24. Soh JW, Weinstein IB: Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. J Biol Chem 2003, 278:34709-34716.
25. Alekseev OM, Bencic DC, Richardson RT, Widgren EE, O'Rand MG: Overexpression of the Linker histone-binding protein tNASP affects progression through the cell cycle. J Biol Chem 2003, 278:8846-8852.
26. Varga EV, Hosohata K, Borys D, Navratilova E, Nylen A, Vanderah TW, Porreca F, Roeske WR, Yamamura HI: Antinociception depends on the presence of G protein gamma2-subunits in brain. Eur J Pharmacol 2005, 508:93-98.
27. Gelman IH, Tombler E, Vargas J Jr: A role for SSeCKS, a major protein kinase C substrate with tumor suppressor activity, in cytoskeletal architecture, formation of migratory processes, and cell migration during embryogenesis. Histochemical Journal 2000, 32:13-26.
28. Xu H, Dembski M, Yang Q, Yang D, Moriarty A, Tayber O, Chen H, Kapeller R, Tartaglia LA: Dual specificity mitogen-activated protein (MAP) kinase phosphatase-4 plays a potential role in insulin resistance. J Biol Chem 2003, 278:30187-30192.
29. Furusawa M, Taira T, Iguchi-Ariga SM, Ariga H: AMY-I interacts with S-AKAP84 and AKAP95 in the cytoplasm and the nucleus, respectively, and inhibits cAMP-dependent protein kinase activity by preventing binding of its catalytic subunit to A-kinase-anchoring protein (AKAP) complex. J Biol Chem 2002, 277:50885-50892.
30. Nagata Y, Oda M, Nakata H, Shozaki Y, Kozasa T, Todokoro, K: A novel regulator of G-protein signaling bearing GAP activity for Galphai and Galphaq in megakaryocytes. Blood 2001, 97:3051-3060.
31. Ram PT, Iyengar R: G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation. Oncogene 2001, 20:1601-1606.
32. Liu T, Bohlken A, Kuljaca S, Lee M, Nguyen T, Smith S, Cheung B, Norris MD, Haber M, Holloway AJ, Bowtell DD, Marshall GM: The retinoid anticancer signal: mechanisms of target gene regulation. Br J Cancer 2005, 93:310-318.
33. Ueki K, Kondo T, Kahn CR: Suppressor of cytokine signaling I (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004, 24:5434-5446.
34. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C, Tannapfel A: SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 2005, 24:6699-6708.
35. Raccurt M, Tam SP, Lau P, Mertani HC, Lambert A, Garcia-Caballero T, Li H, Brown RJ, McGuckin MA, Morel G, Waters MJ: Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer 2003, 89:524-532.
36. De Candia P, Benera R, Solit DB: A role for Id proteins in mammary gland physiology and tumorigenesis. Adv Cancer Res 2004, 92:81-94.
37. Stighall M, Manetopoulos C, Axelson H, Landberg G: High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells. Int J Cancer 2005, 115:403-411.
38. Kienast J, Berdel WE: c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions. Cancer Cell 2004, 5:109-110.
39. Provot S, Pouponnot C, Lecoq O, Calothy G, Felder-Schmittbuhl MP: Characterization of a novel quiescence responsive element downregulated by v-Src in the promoter of the neuroretina specific QRI gene. Oncogene 2000, 19:4736-4745.
40. Bernardin-Fried F, Kummalue T, Leijen S, Collector MI, Ravid K, Friedman AD: AMLI/RUNXI increases during GI to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J Biol Chem 2004, 279:15678-15687.
41. Yanagida M, Osato M, Yamashita N, Liqun H, Jacob B, Wu F, Cao X, Nakamura T, Yokomizo T, Takahashi S, Yamamoto M, Shigesada K, Ito Y: Increased dosage of RunxI/AMLI acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene 2005, 24:4477-4485.
42. Yamamoto H, Horiuchi S, Adachi Y, Taniguchi H, Nosho K, Min Y, Imai K: Expression of ets-related transcriptional factor EIAF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. Carcinogenesis 2004, 25:325-332.
43. ST I, Nie Z, Stewart A, Najdovska M, Hall NE, He H, Randazzo PA, Lock P: ARAP3 is transiently tyrosine phosphorylated in cells attaching to fibronectin and inhibits cell spreading in a RhoGAP-dependent manner. J Cell Sci 2004, 117:6071-6084.
44. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS: Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 2004, 10:7475-7483.
45. Chan AS, Tsui WY, Chen X, Chu KM, Chan TL, Chan AS, Li R, So S, Yuen ST, Leung SY: Downregulation of ID4 by promoter hyper-methylation in gastric adenocarcinoma. Oncogene 2003, 22:6946-6953.
46. Takenaka K, Ogawa E, Oyanagi H, Wada H, Tanaka F: Carbonyl reductase expression and its clinical significance in non-small-cell lung cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1972-1975.
47. Manda R, Kohno T, Matsuno Y, Takenoshita S, Kuwano H, Yokota J: Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display. Genomics 1999, 61:5-14.
48. Ikehara M, Oshita F, Sekiyama A, Hamanaka N, Saito H, Yamada K, Noda K, Kameda Y, Miyagi Y: Genome-wide cDNA microarray screening to correlate gene expression profile with survival in patients with advanced lung cancer. Oncol Rep 2004, 11:1041-1044.
49. Vairapandi M, Balliet AG, Hoffman B, Liebermann DA: GADD45b and GADD45g are cdc2/cyclinBI kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress. J Cell Physiol 2002, 192:327-338.
50. Zhang X, Ma L, Enkemann SA, Pledger WJ: Role of Gadd45alpha in the density-dependent GI arrest induced by p27(Kip 1). Oncogene 2003, 22:4166-4174.
51. Yang J, Kiefer S, Rauchman M: Characterization of the gene encoding mouse retinoblastoma binding protein-7, a component of chromatin-remodeling complexes. Genomics 2002, 80:407-415.
52. Zhu Y, Carroll M, Papa FR, Hochstrasser M, D'Andrea AD: DUB-1, a deubiquitinating enzyme with growth-suppressing activity. Proc Natl Acad Sci USA 1996, 93:3275-3279.
53. Shin I, Kim S, Song H, Kim HR, Moon A: H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem 2005, 280:14675-14683.
54. Zhu Y, Hollmen J, Raty R, Aalto Y, Nagy B, Elonen E, Kere J, Mannila H, Franssila K, Knuutila. S: Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Hoematol 2002, 119:905-915.
55. Tsujimoto K, Ono T, Sato M, Nishida T, Oguma T, Tadakuma T: Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis. J Biol Chem 2005, 280:27638-27644.
56. Jiang BH, Agani F, Passaniti A, Semenza GL: V-SRC induces expression of hypoxia-inducible factor I (HIF-I) and transcription of genes encoding vascular endothelial growth factor and enolase I: involvement of HIF-I in tumor progression. Cancer Res 1997, 57:5328-5335.
57. Gleadle JM, Ratcliffe PJ: Induction of hypoxia-inducible factor-I, erythropoietin, vascular endothelial growth factor, and glucose transporter-I by hypoxia: evidence against a regulatory role for Src kinase. Blood 1997, 89:503-509.
58. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE: HIF-lalpha, STAT3, CBP/p300 and Ref-I/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005, 24:3110-3120.
59. Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A: Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-I alpha expression under normoxia. J Biol Chem 2002, 277:42919-42925.
60. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A, Chajut A, Kalinski H, Kamer I, Rozen A, Mor O, Keshet E, Leshkowitz D, Einat P, Skaliter R, Feinstein E: Identification of a novel hypoxia-inducible factor I-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 2002, 22:2283-2293.
61. Wang XY, Li Y, Manjili MH, Repasky EA, Pardoll DM, Subjeck JR: Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor. Cancer Immunol Immunother 2002, 51:311-319.
62. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, Seed B, Avruch J: Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 2002, 12:253-265.
63. Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG: Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell 2004, 13:341-355.
64. Hakak Y, Hsu YS, Martin GS: Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt. Oncogene 2000, 19:3164-3171.
65. Weernink PA, Meletiadis K, Hommeltenberg S, Hinz M, Ishihara H, Schmidt M, Jakobs KH: Activation of type 1 phosphatidylinositol 4-phosphate 5-kinase isoforms by the Rho GTPases, RhoA, Rac1, and Cdc42. J Biol Chem 2004, 279:7840-7849.
66. Yen A, Lin DM, Lamkin TJ, Varvayanis S: retinoic acid, bromodeoxyuridine, and the Delta 205 mutant polyoma virus middle T antigen regulate expression levels of a common ensemble of proteins associated with early stages of inducing HL-60 leukemic cell differentiation. In Vitro Cell Dev Biol Anim 2004, 40:216-241.
67. He HY, Fang WG, Zheng J, You JF, Heng WJ, Li Y: [Mechanism of the mitogen-activated protein kinase phosphatase-5 regulating the growth and invasion of a human prostate cancer cell line]. Zhonghua Yi Xue Za Zhi 2003, 83:1812-1817.
68. Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, Salovaara R, Nissen AM, Salo J, Mattson K, Hollmen J, Knuutila S, Wikman H: Differentially expressed genes innonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 2004, 149:98-106.
69. Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin MF, Batra SK: Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol 2003, 23:1365-1371.
70. Nakahara T, Tominaga K, Koseki T, Yamamoto M, Yamato K, Fukuda J, Nishihara T: Growth/differentiation factor-5 induces growth arrest and apoptosis in mouse B lineage cells with modulation by Smad. Cell Signal 2003, 15:181-187.
71. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K: Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005, 24:1809-1819.
72. Ciccarelli C, Philipson L, Sorrentino V.: Regulation of expression of growth arrest-specific genes in mouse fibroblasts. Mol Cell Biol 1990, 10:1525-1529.
73. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D: Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 2005, 11:5146-5152.
74. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y, Khanna R, Tamburini P, Swaroop A, Kandpal RP: Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 2006, 25:2328-2338.